ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0140

Continued Treatment with Nintedanib in Patients with Progressive Fibrosing Autoimmune Disease-Related Interstitial Lung Diseases (ILDs): Data from INBUILD-ON

Eric Matteson1, Danielle Antin-Ozerkis2, Francesco Bonella3, Nazia Chaudhuri4, Vincent Cottin5, Heiko Müller6, Carl Coeck7, Klaus Rohr8 and Wim Wuyts9, 1Mayo Clinic College of Medicine and Science, Rochester, MN, USA, Rochester, MN, 2Section of Pulmonary, Critical Care and Sleep Medicine, Yale University School of Medicine, New Haven, CT, 3Center for Interstitial and Rare Lung Diseases, Pneumology Department, Ruhrlandklinik, University of Duisburg-Essen, Essen, Germany, 4North West Interstitial Lung Disease Unit, Manchester University Foundation Trust, Wythenshawe, Manchester, United Kingdom, 5Coordinating Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, University of Lyon, INRAE, Lyon, France, 6Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany, Biberach, Germany, 7Boehringer Ingelheim SComm, Brussels, Brussels, Belgium, 8Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, 9Unit for Interstitial Lung Diseases, Department of Pulmonary Medicine, University Hospitals Leuven, Leuven, Belgium, Leuven, Belgium

Meeting: ACR Convergence 2022

Keywords: autoimmune diseases, clinical trial, interstitial lung disease, pulmonary

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 12, 2022

Title: Miscellaneous Rheumatic and Inflammatory Diseases Poster I

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: In the INBUILD trial in patients with progressive fibrosing ILDs other than idiopathic pulmonary fibrosis, nintedanib reduced the rate of decline in forced vital capacity (FVC) compared with placebo, with adverse events that were manageable for most patients. INBUILD-ON is an open-label extension study that is collecting data on adverse events and FVC decline in patients treated with nintedanib over the longer term. We analyzed data from the subgroup of patients with progressive pulmonary fibrosis due to autoimmune disease.

Methods: Patients in the INBUILD trial had diffuse fibrosing ILD (reticular abnormality with traction bronchiectasis, with or without honeycombing) of >10% extent on HRCT, FVC ≥45% predicted, DLco ≥30%–< 80% predicted, and met criteria for progression of ILD within the prior 24 months, despite management deemed appropriate in clinical practice. Patients who completed the INBUILD trial on treatment were eligible to enter INBUILD-ON. Patients who received nintedanib in INBUILD and continued nintedanib in INBUILD-ON comprised the “continued nintedanib” group. Patients who received placebo in INBUILD and initiated nintedanib in INBUILD-ON comprised the “initiated nintedanib” group. Dose reductions and treatment interruptions were allowed to manage adverse events. In descriptive analyses, we analyzed adverse events and changes in FVC in INBUILD-ON in patients with autoimmune disease-related ILDs based on a data snapshot taken on 15 October 2021.

Results: Of the 434 patients treated in INBUILD-ON, 113 had autoimmune disease-related ILDs (52 RA-ILD, 29 SSc-ILD, 13 MCTD-ILD, 19 other autoimmune disease-related ILDs). Of these, 64.6% received ≥1 disease-modifying anti-rheumatic drug or high-dose glucocorticoid ( >20 mg/day prednisone or equivalent) during the trial. The most frequently reported adverse event was diarrhea (Table). Serious adverse events were reported in 26 (50.0%) patients in the continued nintedanib group and 35 (57.4%) patients in the initiated nintedanib group. Among patients who continued and initiated nintedanib, respectively, 7 (13.5%) and 31 (50.8%) had ≥1 dose reduction and 15 (28.8%) and 26 (42.6%) had ≥1 treatment interruption. Adverse events led to discontinuation of nintedanib in 12 (23.1%) patients in the continued nintedanib group and 26 (42.6%) patients in the initiated nintedanib group. Mean (SE) changes in FVC from baseline to week 96 of INBUILD-ON were −61.3 (39.8) mL in the continued nintedanib group and −62.5 (49.4) mL in the initiated nintedanib group (Figure).

Conclusion: The adverse event profile of nintedanib in patients with progressive pulmonary fibrosis related to autoimmune disease in INBUILD-ON was consistent with that reported in the INBUILD trial. Dose adjustments, treatment interruptions and permanent discontinuations of nintedanib were less frequent in patients who continued nintedanib in INBUILD-ON than in those who initiated nintedanib in INBUILD-ON.

Supporting image 1

Supporting image 2


Disclosures: E. Matteson, UpToDate, Boehringer Ingelheim, Gilead Sciences, Practice Point Communications, Horizon Therapeutics, American College of Rheumatology; D. Antin-Ozerkis, Boehringer Ingelheim, Fibrogen, Pliant, Galecto, Galapagos, Genentech/Roche, BMS; F. Bonella, Boehringer Ingelheim, Boehringer Ingelheim, Fujirebio, Galapagos NV, Roche, Roche, Bristol Myers Squibb, GlaxoSmithKline, Takeda; N. Chaudhuri, Boehringer Ingelheim, Redx, Liminal BioSciences, Vicore Pharma AB, Bridge Biotherapeutics, tranScrip Ltd; V. Cottin, Boehringer Ingelheim, Roche, Shionogi, RedX, PureTech, Celgene/BMS, AstraZeneca, XSL Behring, Sanofi, United Therapeutics, Pliant, Boehringer Ingelheim, Roche, Galapagos, Celgene/BMS, CSL Behring, Galecto, Fibrogen; H. Müller, Boehringer Ingelheim; C. Coeck, Boehringer Ingelheim; K. Rohr, Boehringer Ingelheim; W. Wuyts, Boehringer Ingelheim, Roche, Galapagos.

To cite this abstract in AMA style:

Matteson E, Antin-Ozerkis D, Bonella F, Chaudhuri N, Cottin V, Müller H, Coeck C, Rohr K, Wuyts W. Continued Treatment with Nintedanib in Patients with Progressive Fibrosing Autoimmune Disease-Related Interstitial Lung Diseases (ILDs): Data from INBUILD-ON [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/continued-treatment-with-nintedanib-in-patients-with-progressive-fibrosing-autoimmune-disease-related-interstitial-lung-diseases-ilds-data-from-inbuild-on/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/continued-treatment-with-nintedanib-in-patients-with-progressive-fibrosing-autoimmune-disease-related-interstitial-lung-diseases-ilds-data-from-inbuild-on/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology